InSilico Medicine Cayman TopCo (3696.HK) on Monday announced partnership with SK Biopharmaceuticals Co., Ltd. (326030.KS) to discover artificial intelligence-enabled drug candidates targeting neuroimmune disorders of the central nervous system, in a deal worth more than $2.5 billion.
Under the agreement, Insilico will use its proprietary Pharma.AI platform to discover and optimize drug candidates for neuroinflammatory, neurodegenerative and rare neurological diseases, while SK Biopharmaceuticals will lead late-stage development and commercialization.
Insilico said it will be eligible to receive up to $18 million in upfront and near-term milestone payments. The agreement also includes development, regulatory and commercial milestone payments, as well as single-digit royalties on net sales.
The collaboration was announced at the BIO 2026 International Convention.
Insilico, a clinical-stage biotechnology company focused on AI-driven drug discovery, said its platform has helped shorten preclinical drug development timelines, with the company nominating 31 preclinical candidates since 2021, including 13 programs that have received investigational new drug approvals or clearances.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.